IMMX

NASDAQ 已收盘

Immix Biopharma

7.04 USD
▼-0.07-0.98%
盘后 6.94 -1.42%
2026-11-19
市值
$583.33M
市盈率
—
EPS
-0.79
股息率
—
52 周区间
3.78 – 15.10
成交量
1.13M
Beta
0.29
目标价
23.91
52W 低 3.7852W 高 15.10
价格走势

公司简介

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.